Skip to main content
PMC home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 Sep;113(1):5–6. doi: 10.1111/j.1476-5381.1994.tb16165.x

Close correlation of the cardioprotective effect of FK409, a spontaneous NO releaser, with an increase in plasma cyclic GMP level.

Y Kita 1, T Sugimoto 1, Y Hirasawa 1, K Yoshida 1, K Maeda 1
PMCID: PMC1510085  PMID: 7812632

Abstract

FK409 ((+/-)-(E)-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexeneamide) , which has been reported by us to be a new spontaneous nitric oxide (NO) releaser, prevented myocardial infarction following occlusion and reperfusion in rat coronary artery and increased plasma cyclic GMP level in rats, dose-dependently and significantly at 32 mg kg-1. Isosorbide dinitrate (ISDN), which is the most popular orally active NO donor used in the treatment of ischaemic cardiovascular diseases, did not show significant effects at 32 mg kg-1 in either experiment. Therefore, it is suggested that FK409 can attenuate myocardial injury during ischaemia and reperfusion in contrast to ISDN and a change in plasma cyclic GMP level may serve as an indicator of the cardioprotective effect of NO-releasing drugs.

Full text

PDF
5

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bednar M., Smith B., Pinto A., Mullane K. M. Neutrophil depletion suppresses 111In-labeled platelet accumulation in infarcted myocardium. J Cardiovasc Pharmacol. 1985 Sep-Oct;7(5):906–912. doi: 10.1097/00005344-198509000-00014. [DOI] [PubMed] [Google Scholar]
  2. Feelisch M., Noack E. A. Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol. 1987 Jul 2;139(1):19–30. doi: 10.1016/0014-2999(87)90493-6. [DOI] [PubMed] [Google Scholar]
  3. Feelisch M., Noack E. Nitric oxide (NO) formation from nitrovasodilators occurs independently of hemoglobin or non-heme iron. Eur J Pharmacol. 1987 Oct 27;142(3):465–469. doi: 10.1016/0014-2999(87)90090-2. [DOI] [PubMed] [Google Scholar]
  4. Kanayama T., Kimura Y., Tamao Y., Mizogami S. Beneficial effects of a new prostacyclin analogue, KP-10614, on acute myocardial infarction in rats. J Cardiovasc Pharmacol. 1992 Oct;20(4):630–637. doi: 10.1097/00005344-199210000-00017. [DOI] [PubMed] [Google Scholar]
  5. Kita Y., Hirasawa Y., Maeda K., Nishio M., Yoshida K. Spontaneous nitric oxide release accounts for the potent pharmacological actions of FK409. Eur J Pharmacol. 1994 May 12;257(1-2):123–130. doi: 10.1016/0014-2999(94)90703-x. [DOI] [PubMed] [Google Scholar]
  6. Laws K. H., Clanton J. A., Starnes V. A., Lupinetti F. M., Collins J. C., Oates J. A., Hammon J. W., Jr Kinetics and imaging of indium-11-labeled autologous platelets in experimental myocardial infarction. Circulation. 1983 Jan;67(1):110–116. doi: 10.1161/01.cir.67.1.110. [DOI] [PubMed] [Google Scholar]
  7. Shotan A., Mehra A., Ostrzega E., Hsueh W., Do Y. S., Fisher D. A., Hurst A., Johnson J. V., Elkayam U. Plasma cyclic guanosine monophosphate in chronic heart failure: hemodynamic and neurohormonal correlations and response to nitrate therapy. Clin Pharmacol Ther. 1993 Dec;54(6):638–644. doi: 10.1038/clpt.1993.201. [DOI] [PubMed] [Google Scholar]
  8. Smith E. F., 3rd, Griswold D. E., Egan J. W., Hillegass L. M., DiMartino M. J. Reduction of myocardial damage and polymorphonuclear leukocyte accumulation following coronary artery occlusion and reperfusion by the thromboxane receptor antagonist BM 13.505. J Cardiovasc Pharmacol. 1989 May;13(5):715–722. [PubMed] [Google Scholar]
  9. Stahl G. L., Terashita Z., Lefer A. M. Role of platelet activating factor in propagation of cardiac damage during myocardial ischemia. J Pharmacol Exp Ther. 1988 Mar;244(3):898–904. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES